← Leaderboards
Tanya Maria Laidlaw
Brigham And Women'S Hospital
$5,208,119
Attributed
$5,208,119
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $616.5K · FY2012–25$1M$750K$500K$250K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,208,119 · 4
By mechanism
R01$2,218,542 · 1
U19$1,920,075 · 1
K23$721,440 · 1
K24$348,062 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Joshua A Boyce$54,050,346
- Charles Nicholas Serhan$33,627,216
- Elliot Israel$35,880,602
- Bruce D Levy$29,805,980
- Nora Amanda Barrett$12,519,597
Others in their field
Top investigators on “Nose”
- Lawrence Corey · Fred Hutchinson Cancer Center$24,903,100
- Barney Sparrow · Battelle Memorial Institute$23,375,525
- Carlos A. Camargo · Brigham And Women'S Hospital$21,312,448
- George M Weinstock · Baylor College Of Medicine$20,235,503
- Robert P Schleimer · Johns Hopkins University$16,011,411
- Ravi Kalhan · Northwestern University At Chicago$15,411,918
Research focus
NoseNasal PolypsInflammatoryAffectPolyposisSinusInflammationTissuesAsthmaPharmaceutical PreparationsProductionRespiratoryChronicAdultSyndromeCysteinyl-LeukotrieneRecurrenceDiagnosisAspirin-Exacerbated Respiratory DiseaseLinkEffector CellAnosmiaCellsSignal Transduction
Grant awards (17)
Project 3. Mechanisms of benefit of biologic agents for patients with aspirin-exacerbated respiratory disease (AERD)$414,631
U19 · FY2025 · AI · contact PI
Patient-Oriented Research Mentorship and Training in Upper Airway Allergic and Inflammatory Diseases$174,031
K24 · FY2025 · AI · contact PI
Project 3. Mechanisms of benefit of biologic agents for patients with aspirin-exacerbated respiratory disease (AERD)$318,002
U19 · FY2024 · AI · contact PI
Patient-Oriented Research Mentorship and Training in Upper Airway Allergic and Inflammatory Diseases$174,031
K24 · FY2024 · AI · contact PI
Project 3. Mechanisms of benefit of biologic agents for patients with aspirin-exacerbated respiratory disease (AERD)$372,218
U19 · FY2023 · AI · contact PI
Project 3. Mechanisms of benefit of biologic agents for patients with aspirin-exacerbated respiratory disease (AERD)$431,586
U19 · FY2022 · AI · contact PI
Project 3. Mechanisms of benefit of biologic agents for patients with aspirin-exacerbated respiratory disease (AERD)$383,638
U19 · FY2021 · AI · contact PI
Prostaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory Disease$443,750
R01 · FY2019 · HL · contact PI
Prostaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory Disease$443,750
R01 · FY2018 · HL · contact PI
Prostaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory Disease$443,750
R01 · FY2017 · HL · contact PI
Prostaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory Disease$443,750
R01 · FY2016 · HL · contact PI
The inflammatory role of the platelet in aspirin-exacerbated respiratory disease.$172,800
K23 · FY2016 · HL · contact PI
Prostaglandin D2: A Key Mediator of Aspirin-Exacerbated Respiratory Disease$443,542
R01 · FY2015 · HL · contact PI
The inflammatory role of the platelet in aspirin-exacerbated respiratory disease.$137,160
K23 · FY2015 · HL · contact PI
The inflammatory role of the platelet in aspirin-exacerbated respiratory disease.$137,160
K23 · FY2014 · HL · contact PI
The inflammatory role of the platelet in aspirin-exacerbated respiratory disease.$137,160
K23 · FY2013 · HL · contact PI
The inflammatory role of the platelet in aspirin-exacerbated respiratory disease.$137,160
K23 · FY2012 · HL · contact PI